Xencor and Genentech, a member of the Roche Group, are co-developing XmAb24306 and other potential novel IL15 cytokine therapeutics. XmAb24306 is an IL15/IL15Rα cytokine complex engineered with Xencor’s bispecific Fc domain and Xtend™ Fc technology. Additionally, the companies have engaged in a two-year research program to discover new IL15 drug candidates, including ones targeted to specific immune cell populations. The companies are will share development costs and profits. Genentech will commercialize medicines worldwide, and Xencor has the option to co-promote in the United States.